covid occurred in conjunction with the bleeding, around 28jan2022; covid occurred in conjunction with the bleeding, around 28jan; this is a spontaneous report received from a contactable reporter(s) (other hcp) from the regulatory authority-web and product quality group. a 43 year-old female patient received bnt162b2 (comirnaty), intramuscular, administered in arm right, administration date 06nov2021 17:15 (lot number: fg3739) as dose 3 (booster), single, intramuscular, administered in deltoid left, administration date 13mar2021 11:24 (lot number: et1831) as dose 2, single and intramuscular, administered in deltoid left, administration date 20feb2021 10:29 (lot number: ep9598) as dose 1, single for covid-19 immunisation. the patient's relevant medical history was not reported. concomitant medication(s) included: achillea; alchemilla spp.; melatonin; broncho vaxom adult. the following information was reported: vaccination failure (medically significant) with onset 28jan2022, outcome "unknown", described as "covid occurred in conjunction with the bleeding, around 28jan2022"; covid-19 (medically significant) with onset 28jan2022, outcome "unknown", described as "covid occurred in conjunction with the bleeding, around 28jan". the patient underwent the following laboratory tests and procedures: blood test: samples to check anaemia and iron. no follow-up attempts are possible. no further information expected. follow-up (28feb2022): follow-up attempts are completed. no further information is expected.; sender's comments: linked report(s) : it-pfizer inc-202200293907 same patient and suspect drug, different events

test name: blood samples; result unstructured data: test result:samples to check anaemia and iron

na

na